News

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...
Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention
Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...
Zacks Investment Research on MSN4d
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...
PharmExec3d
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation
The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of ...
pharmaphorum4d
There's good news for RSV jab firms at delayed ACIP meeting
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Pharmabiz2d
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
This includes Abrysvo (Respiratory Syncytial Virus Vaccine), which in October 2024, the US Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at ...
Morningstar5d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...
Seeking Alpha4d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...